bluuebunny/crossref_metadata_2025_split huggingface dataset:
#2373 Malignant tumors of the urinary bladder and Balkan endemic nephropathy – a 45 year study
Authors: Apostolovic Branislav , Glogovac Stevan , Tasic Danijela , Sterkovic Srdjan , Petrovic Ana , Petrovic Milan , Dimitrijevic Zorica , Paunovic Karolina , Mladenovic Slavoljub , Prokopovic Miomir , Bašić Dragoslav , Mitic Branka 
Published: May 2024

Abstract

Background and Aims
Balkan endemic nephropathy (BEN) is a chronic interstitial kidney disease limited geographically to specific regions. The wider importance of BEN is reflected in its associations with malignant tumors of the urothelium. For researchers, malignant tumors of the urinary bladder (MTUB) have been less studied and perhaps considered less interesting compared to malignant tumors of the upper urothelium. Balkan endemic nephropathy (BEN) is a chronic interstitial kidney disease limited geographically to specific regions. The wider importance of BEN is reflected in its associations with malignant tumors of the urothelium. For researchers, malignant tumors of the urinary bladder (MTUB) have been less studied and perhaps considered less interesting compared to malignant tumors of the upper urothelium.

Method
Balkan endemic nephropathy (BEN) is a chronic interstitial kidney disease limited geographically to specific regions. The wider importance of BEN is reflected in its associations with malignant tumors of the urothelium. For researchers, malignant tumors of the urinary bladder (MTUB) have been less studied and perhaps considered less interesting compared to malignant tumors of the upper urothelium.

Results
During the observed period, there were a total of 1447 cases of MTUB - 1109 (76.64%) male patients and 338 (33.36%) female patients. The average annual incidence rate (AAIR) of MTUB in endemic settlements for the observed period (1978-2024) is 15.64; in hypoendemic areas is 13.89, and in non-endemic areas is 14.62. The AAIR of MTUB in endemic settlements is 1.13 times higher than the rate in hypoendemic areas and 1.07 times higher compared to non-endemic settlements.
It is noteworthy that in the first period of observation, the AAIR of MTUB in endemic areas is 2.24 times higher than the rate in hypoendemic areas and 4.09 times higher than the rate in non-endemic areas. However, in the second and third periods of the study, it is significantly lower compared to the rates in hypoendemic and non-endemic areas.
The linear trend of MTUB for the observed period in endemic settlements is negative without statistical significance (y = −0.012x + 701; r2 = 0.048), while in non-endemic areas, it is positive and statistically significant (y = 1.340x + 0.172; r2 = 0.647).

Conclusion
The higher frequency of MTUB in the Jablanica district over the 45-year study of the region with BEN is limited to the first part of the research and may indicate a common nephropathogenic and carcinogenic etiological factor, confirming a positive correlation between BEN and malignant urothelial tumors. At the same time, in the last 25 years of the observed period, there has been a drastic decline in the frequency of both BEN and MTUB, as well as malignant tumors of the upper urothelium.
#3001 MtDNA copy number correlates to coronary artery calcium score and biological age in kidney failure patients
Authors: Schwarz Angelina , Qureshi Abdul Rashid Tony , Filograna Roberta , Wennberg Lars , Wernerson Annika , Witasp Anna , Stenvinkel Peter 
Published: May 2024

Abstract

Background and Aims
Chronic kidney disease (CKD) and kidney failure are connected to increased oxidative stress and vascular calcification, which are indicators for development of comorbidities and mortality outcome. Mitochondrial (mt)DNA copy number has been reported as independent predictor for frailty and mortality outcome of various cardiovascular diseases (CVD) and cancer.
We aimed that mtDNA copy number in whole blood of kidney failure patients can be correlated to coronary artery media calcification score and coronary artery calcium (CAC) score and be used as an independent predictor for comorbidities and mortality outcome.

Method
Quantitative PCR (qPCR) with TaqMan® probes for three mtDNA genes (mtND1, mtND4 and mtCOX1) and two single locus genes on nuclear DNA (hemoglobin subunit beta and 18S), for normalization, is performed on DNA samples isolated from collected blood of 196 kidney transplant donors and 211 recipients at basal timepoint and 32 at 1-year-follow-up timepoint, included in the KaroKidney biobank. Resulting mtDNA copy number is investigated for correlation to CAC score, patient mortality outcome, biological age determined by skin autofluorescence and other clinical parameters.

Results
In our Swedish kidney transplant cohort we can see statistically significant difference in mtDNA copy number between kidney failure patients (recipients) and healthy controls (donors). No obvious difference between females and males was observed. mtDNA copy number correlates to biological age determined by skin autofluorescence, CAC score and Framingham CVD risk score. In the 32 1-year-follow-up samples we could see significant increase/recovery of mtDNA copy number for male patients compared to their baseline before receiving a transplant.

Conclusion
In this study we show that mtDNA copy number in kidney failure patients correlates to biological age and CAC score, affirming mtDNA copy number as an independent predictor of frailty in this Swedish cohort of CKD patients. Additionally, we can see that a kidney transplant can lead to a significant increase of mtDNA copy number in blood one year later, suggesting a general increase in health quality.
#2147 Enoxaparin dosing in advanced chronic kidney disease: importance of monitoring with anti-Xa levels
Authors: Corona Clara Maria Cases , Melero Eva López , Triska Eugenia Landaluce , León Mariana , Roldán Deborah , Gruss Enrique , Shabaka Amir 
Published: May 2024

Abstract

Background and Aims
Enoxaparin is a low-molecular-weight heparin (LMWH) that is commonly used in the prevention of deep venous thrombosis (DVT) and the treatment of acute thomboembolic diseases. Current literature indicates that in advanced chronic kidney disease (CKD), there is a reduced clearance and increased half-life of LMWH and therefore, a dose adjustment is recommended. The prescription label recommends a dose adjustment of enoxaparin to 0.5 mg/kg/day for prophylaxis of DVT and 1 mg/kg/day for therapeutic anticoagulation when eGFR &lt;30 ml/min. The aim of this study was to examine the accuracy of this dosing strategy to achieve the desired target of anticoagulation in advanced CKD.

Method
We conducted a prospective study in patients admitted from May 2019 to April 2023 in the Nephrology ward at our centre, who started anticoagulant treatment with enoxaparin during their in-hospital stay for prophylactic or therapeutic indications. We excluded patients with eGFR &gt;30 ml/min at the onset of anticoagulation with enoxaparin. The dosing strategy was 0.5 mg/kg/day for prophylaxis of DVT and 1 mg/kg/day for therapeutic anticoagulation in all patients. Blood samples were drawn 4 hours after the third dose of enoxaparin to monitor anti-Xa levels in all cases.

Results
The study included 153 patients; 70 patients with stage 4-5 CKD and 83 patients on renal replacement therapy. 132 patients (86.3%) received enoxaparin for a therapeutic indication, while 21 patients (13.7%) received it as prophylaxis of DVT.
In patients receiving enoxaparin for a therapeutic indication, 73 patients (55.3%) reached the therapeutic target anti-Xa levels (0.6-1), while 32.6% of patients had peak anti-Xa levels below the therapeutic target (&lt;0.6) and 12.1% were over-anticoagulated (&gt;1). There was an inverse relationship between the proportion of patients who were adequately anticoagulated and CKD stage; 66.7%, 58.6% and 48.6% of patients reached the target peak anti-Xa levels in CKD stage 4, 5 and 5D respectively. There was no significant association between anti-Xa levels and obesity or liver disease.
In patients receiving enoxaparin for prophylaxis of DVT, 42.9% reached the target anti-Xa levels for prophylaxis (0.3-0.6), while 38.1% had anti-Xa levels below this range and 19% were over-anticoagulated.

Conclusion
The enoxaparin dosing recommendations indicated by its label entails a high proportion of patients with advanced CKD who do not achieve the target therapeutic levels of antiXa, especially in patients on renal replacement therapy.
To ensure adequate anticoagulation in these patients, we recommend using individualized dosing adjustments based on monitoring of anti-Xa levels for the prevention of thromboembolic events and reducing the risk of hemorrhagic events.
#1429 Daily urinary potassium excretion is not a fixed percentage of daily potassium intake
Authors: van Vliet Anne Myrthe , Rauh Manfred , Vogt Liffert , Titze Jens , Engberink Rik Olde 
Published: May 2024

Abstract

Background and Aims
High potassium intake is associated with a lower blood pressure and lower incidence of chronic kidney disease. Since a significant amount of potassium is lost via stool, the World Health Organization advices to multiply 24-hour renal potassium excretion by 1.3 for estimation of dietary intake. We analyzed whether this 1.3 factor for potassium intake varies in healthy volunteers and evaluated whether factors associated with tissue cation storage, namely sodium intake, aldosterone, cortisol and urine volume, affect the renal potassium excretion.

Method
We performed a post-hoc analysis of the long-term sodium balance studies Mars105 and Mars520. Ten healthy male participants consumed a fixed amount of salt (6, 9 and 12 grams/day for &gt;29 days) and potassium (4 grams/day) for 105 (n = 4) and 205 days (n = 6). During the entire study period all urine was collected in 24-hour aliquots. We calculated the percentage of potassium intake that was excreted in the corresponding 24-hour urine collection during steady-state. We assessed whether this percentage was associated with sodium intake, potassium intake, urinary aldosterone, urinary cortisol and urine volume using a multivariable mixed-effects model.

Results
Overall, the median renal potassium excretion was 80% of potassium intake (IQR 65-97%; range 24-304%). This corresponds to a conversion factor of 1.25 (IQR 1.03-1.54). Within individual subjects we also observed a marked day-to-day variation in the percentage of renal potassium excretion: the average intraperson width of the IQR was 25%.
A higher sodium intake was associated with an increased percentage of renal potassium excretion, whereas a higher potassium intake was associated with a decreased percentage of renal potassium excretion. A significant positive interaction between the effects of sodium and potassium intake was present (P &lt; .001; Fig. A). Furthermore, urinary aldosterone (Fig. B), urinary cortisol (Fig. C) and urine volume (Fig. D) were positively associated with the percentage of renal potassium excretion.

Conclusion
The percentage of consumed potassium that is excreted via urine shows considerable intra- and inter-subject variability. During steady-state this percentage is independently affected by sodium intake, potassium intake, urinary aldosterone, urinary cortisol, and urine volume. Our results suggest that the WHO's fixed 1.3 conversion factor may lead to inaccurate estimations of potassium intake.
#951 Structural and functional indicators of the left heart in the aspect of contrast-induced nephropathy
Authors: Daminova L T , Kadirovich Muminov Davron , Muminova Sitora 
Published: May 2024

Abstract

Background and Aims
To study the structural and functional features of the left heart in patients with coronary artery disease depending on the development of contrast-induced nephropathy (CIN) against the background of radiopaque endovascular procedures (REP).

Method
The study included 303 patients with stable forms of coronary artery disease who underwent X-ray endovascular procedures (REP). Patients with eGFR, determined by serum creatinine concentration, less than 60 ml/minute were not included in the study. 20 healthy volunteers were examined as a control group. All patients were divided into 2 groups - patients with an uncomplicated postoperative period of REP (CIN- group, 206 patients, 67.99%) and patients who developed contrast-induced nephropathy (CIN+ group, 97 patients, 32.01%). Subsequently, the CIN+ and CIN- groups were retrospectively compared based on baseline echocardiographic parameters.

Results
The present study demonstrated that EchoCG predictors of CIN in patients with stable forms of coronary artery disease are dilatation of the left ventricular (LV) cavity more than 136 ml (relative risk 1.65, p &lt; 0.01), an increase in the index of impaired regional contractility of the LV to 1.2 points or higher (relative risk 1.77, p &lt; 0.01) and a decrease in the e/a ratio of tissue Dopplerogram of the lateral edge of the mitral annulus to 0.7 relative units or less (relative risk 1.59, p &lt; 0.01).

Conclusion
In patients with coronary artery disease after REP, despite the improvement in the index of impaired regional contractility and the index of LV sphericity, in the CIN+ group there is a more significant deterioration in the structural and functional properties of the LV myocardium, which manifested itself in an increase in systolic myocardial stress, a decrease in ejection fraction and an increase in the degree of diastolic dysfunction, which indicates a toxic effect of the radiocontrast drug not only on the kidneys, but also on the myocardium.
#2775 ERCOS multicenter Spanish study: clinical profile of patients with chronic kidney disease G3a-G5D and osteoporosis
Authors: Jiménez Elisabeth Masso , Sanjuan Jordi Bover , Casado Enrique , García Minerva Rodríguez , Lloret Maria Jesus , Alonso Cristina Castro , Henriquez Fernando , Gifre Laia , Calvo José Antonio Herrero , Teruel Jose Luis Górriz , Gómez Carlos , Navarro-González Juan F 
Published: May 2024

Abstract

Background and Aims
Fracture risk evaluation has recently been integrated into the 2017 KDIGO CKD-MBD (Chronic Kidney Disease- Mineral and Bone Disorder) guideline and its 2021 Spanish endorsement. It is now suggested to test bone mineral density (BMD) to assess fracture risk “if results will impact treatment decisions”. In fact, multiple new prospective studies have now documented that lower BMD predicts incident fractures in patients with CKD G3a–G5D. However, we scarcely know current real clinical practice in this population. Thus, the aim of the ERCOS (“Enfermedad Renal Crónica OSteoporosis”) study was to describe the clinical profile of patients with CKD who had been diagnosed of osteoporosis in outpatient Nephrology and Rheumatology clinics in Spain.

Method
ERCOS is a descriptive, observational, and multicenter Spanish study. Patients were recruited by consecutive sampling from 15 different Spanish hospitals. Osteoporosis characteristics (history of fragility fracture, BMD and other fracture risk factors), associated comorbidities, biochemical parameters and treatment were analyzed.

Results
A total of 163 patients (median age 77 years old) were included. Most were women (71.2%) and 98.3% of them were postmenopausal. Hypertension was the most frequent comorbidity (87.1%) and “attributed” cause of CKD (43.2%). Diabetes mellitus and cardiovascular disease were present in 35.6% and 29.4% of patients, respectively. Median estimated glomerular filtration rate was 36 ml/min/1.73 m2 [creatinine 1.48 mg/dl (95% CI 1,2-2)]. 38% of patients were G5D CKD patients (95.2% undergoing hemodialysis). 37.7% of patients had had a fragility fracture after the diagnosis of CKD (vertebral 52.5%, hip 24.6%, wrist 21.3%, humerus 16.4%, among others). Importantly, despite the diagnosis of osteoporosis, only 60.1% of the patients received specific treatment (mainly bisphosphonates or denosumab). Moreover, antiosteoporotic treatment was much more frequently prescribed by rheumatologists (46.9%), internal medicine physicians (23.5%), and only 13.3% was prescribed by nephrologists. 19.4% of patients suffered from fragility fractures even after initiating specific treatment.

Conclusion
Most patients with moderate and severe CKD with osteoporosis were old postmenopausal women with a high prevalence of diabetes or cardiovascular disease. Although about 40% had even suffered a fragility fracture, there is a high treatment gap, especially relevant among nephrologists. A call to action and to avoid existing therapeutic nihilism seems necessary, expanding the knowledge of the new more proactive guidelines and homogenizing the care and therapeutic approach in these patients.
#1051 Association between anemia/iron deficiency and health-related quality of life in patients with advanced CKD: the Reach-J CKD cohort study
Authors: Okubo Reiko , Ohigashi Tomohiro , Kondo Masahide , Tsunoda Ryoya , Kai Hirayasu , Saito Chie , Okada Hirokazu , Narita Ichiei , Hoshino Junichi , Maruyama Shoichi , Wada Takashi , Yamagata Kunihiro 
Published: May 2024

Abstract

Background and Aims
Low Hb and low TSAT levels are associated with worse health-related quality of life (HRQOL) in patients from Brazil, France and USA in the CKD outcomes and Practice Patterns Study (CKDopps). However, there is little evidence for those in Asian countries. We aimed to evaluate the association between anemia/iron deficiency and HRQOL in Japan.

Method
We conducted a nationwide cohort study of Japanese patients with advanced CKD. We recruited 2249 patients with stage G3b-5 CKD receiving nephrologist care from 31 representative facilities throughout Japan, randomly selected with stratification by region and facility size, aligned with the CKDopps. The association between Hb and TSAT levels at enrolment and HRQOL derived from KDQOL-36 was evaluated.

Results
Mean age was 69.1 ± 12.6 years; 35.2% were female; mean body mass index was 23.6 ± 4.8 kg/m, mean eGFR was 23.2 ± 10.5 mL/min/1.73 m2. Mean Hb was 11.7 g/dL, mean TSAT was 31.4% and ferritin was 147.4 ng/mL. The mean physical component summary (PCS) scores, mental component summary (MCS) scores and scores on the three KDQOL subscales were worse with Hb &lt;10, compared to ≥10 g/dL. Few differences in PCS and MCS scores were seen between the TSAT levels.

Conclusion
In Japanese patients with CKD, HRQOL was worse with Hb &lt;10 g/dL and not associated with TSAT levels. These data will provide important information for international comparisons and the clinical practice of Asian patients with CKD.
#708 Retrospective analysis of the real-world experience of desidustat in the treatment of chronic kidney disease induced anemia
Authors: Pahari Dilip 
Published: May 2024

Abstract

Background and Aims
Chronic kidney disease (CKD) is commonly associated with an increased risk of anemia, which significantly impacts patients' quality of life and increases morbidity and mortality. Current treatment options for anemia in CKD, such as injectable erythropoiesis-stimulating agents (ESAs) have limitations and safety concerns. Desidustat, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) has shown promise in stimulating endogenous erythropoiesis and addressing anemia in CKD. Therefore, the present study assesses the real-world clinical efficacy and safety of the desidustat treatment for a short duration of 6 months (24 weeks) in CKD patients with anemia.

Method
This is a retrospective analysis of 140 patients at our center who received Desidustat as a treatment for CKD anemia. Desidustat was initiated in all patients at 100 mg three times a week. Dose adjustment was done every 4 weeks as per the Hb level of the patient. The duration of the study was 6 months. The primary endpoint of the present study was a change in Hb from baseline with desidustat therapy and the secondary endpoint was safety of the treatment.

Results
The majority of the patients were Pre-dialysis 74.28% (n = 104) and 25.72% (n = 36) were dialysis-dependent patients. Of 36 dialysis-dependent patients; 75% (n = 27) were on dialysis three times a week, rest were on twice-a-week dialysis. In the current study, the majority of patients had Hypertension (95.7%) and diabetes (68.57%) as co-morbidities. All the patients in the current study were maintained with 100 mg Desidustat, however, 9.2% (n = 13) required dose reduction, and 11.42% (n = 16) required an increased dose of desidustat on the follow-up visit. In both Pre-Dialysis and dialysis-dependent patients, there was a sustainable rise in the mean Hb levels at the end of 24 weeks from baseline (1.05 g/dL; p &lt; 0.05) All the patients tolerated desidustat well. In the present study, we didn't observe significant side effects related to the therapy apart from 2.41% (n = 3) cases of Diarrhoea and Vomiting.

Conclusion
Desidustat is effective in increasing Hb in CKD Anemia patients in the short run. However, Long-term studies are required to establish the efficacy and safety of this novel therapy.
#1452 Halting the progression of chronic kidney disease; an audit of the use of renin-angiotensin-aldosterone blockers and SGLT-2 inhibitors
Authors: Teh Jia Wei , Harris Luke , Corcoran Niamh , Lappin David 
Published: May 2024

Abstract

Background and Aims
Sodium-glucose cotransporters-2 inhibitors (SGLT2i) were initially developed for the treatment of type 2 diabetes. Multiple studies have demonstrated the renoprotective effect of SGLT2i, with the capacity to slow diabetic kidney disease and non-diabetic proteinuric chronic kidney disease progression. More recently, the EMPA-KIDNEY trial demonstrated a benefit in patients with chronic kidney disease with a wider range of albuminuria and glomerular filtration rate. We aim to identify the proportion of patients on renin-angiotensin aldosterone system blockade (RAASb) such as angiotensin converting enzyme inhibitor (ACEi), and angiotensin II receptor blocker (ARB), and sodium-glucose transporter-2 inhibitor (SGLT2i) in our Nephrology outpatients clinic. We also aim to encourage awareness and prescribing of RAASb and SGLT2i in eligible patients with CKD.

Method
A prospective audit was performed in Galway University Hospital (GUH) from September 2023 to October 2023. The audit questionnaire was completed by doctors reviewing patients in OPD. The use of ACEi/ARB/SGLT2i was recorded during the consultation.

Results
165 patients were included in the audit with a mean (±SD) age of 62.1 ± 18.6 years. The 3 most common primary renal diagnoses were diabetic kidney disease; 20/165 (12.1%), hypertensive renal disease; 18/165 (10.9%) and IgA nephropathy; 15/165 (9.1%). The mean estimated glomerular filtration rate (eGFR) was 46.8 ± 24.5 ml/min/1.73 m². At baseline, 94/165 (57%) were already on RAASb, none on dual RAASb agents. 20/165 (12.1%) were already on SGLT2i, amongst these, 15/20 (75%) were also on RAASb at the time of the OPD consultation. 13/165 (7.9%) patients were maximised on RAASb and 4/165 (2.4%) commenced an SGLT2i at the clinic visit. Guideline directed medical therapy according to the EMPA-Kidney and UK Kidney Association Clinical Practice Guidelines would suggest missed opportunity on therapeutic optimisation with RAASb and SGLT2i in 66/83 (79.5%) patients; 26/66 (39.4%) were neither on RAASb or SGLT2i, 34/66 (51.5%) were on RAASb but not on SGLT2i, 3/66 (4.5%) were on SGLT2i but not on RAASb, and 3/66 (4.5%) were on sub-maximal RAASb with an SGLT2i.

Conclusion
There is new evidence to support the use of SGLT2i, in those with chronic kidney disease with a wide range of albuminuria. SGLT2i use is underutilised in our clinic. Ideally, these patients should be initiated on an SGLT2i after being established on a RAASb early in their diagnosis to ensure the optimal renoprotective effects of SGLT2i.